115 related articles for article (PubMed ID: 23252601)
21. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Sofrygin O; Thomas SK; Papo NL; Barghout V
Clin Breast Cancer; 2007 Jun; 7(8):608-18. PubMed ID: 17592673
[TBL] [Abstract][Full Text] [Related]
22. Predicting compliance in a breast cancer prevention trial.
Maurice A; Howell A; Evans DG; O'Neil AC; Scobie S
Breast J; 2006; 12(5):446-50. PubMed ID: 16958964
[TBL] [Abstract][Full Text] [Related]
23. [Breakthrough in breast cancer chemoprevention].
Kahán Z; Thurzó L
Orv Hetil; 2003 Mar; 144(13):597-603. PubMed ID: 12728784
[TBL] [Abstract][Full Text] [Related]
24. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
25. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.
Grann VR; Jacobson JS; Whang W; Hershman D; Heitjan DF; Antman KH; Neugut AI
Cancer J Sci Am; 2000; 6(1):13-20. PubMed ID: 10696733
[TBL] [Abstract][Full Text] [Related]
26. The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.
Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Pollard S; Clack G; Cuzick J; Coibion M; Bianco AR
BJOG; 2003 Dec; 110(12):1099-106. PubMed ID: 14664881
[TBL] [Abstract][Full Text] [Related]
27. Healthy women with a family history of breast cancer: impact of a tailored genetic counseling intervention on risk perception, knowledge, and menopausal therapy decision making.
Matloff ET; Moyer A; Shannon KM; Niendorf KB; Col NF
J Womens Health (Larchmt); 2006 Sep; 15(7):843-56. PubMed ID: 16999640
[TBL] [Abstract][Full Text] [Related]
28. Chemoprevention acceptance and adherence in women with high-risk breast lesions.
Roche CA; Tang R; Coopey SB; Hughes KS
Breast J; 2019 Mar; 25(2):190-195. PubMed ID: 29785770
[TBL] [Abstract][Full Text] [Related]
29. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen.
Kimmick GG; Lovato J; McQuellon R; Robinson E; Muss HB
Breast J; 2006; 12(2):114-22. PubMed ID: 16509835
[TBL] [Abstract][Full Text] [Related]
30. Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome.
Formelli F; Camerini T; Cavadini E; Appierto V; Villani MG; Costa A; De Palo G; Di Mauro MG; Veronesi U
Cancer Epidemiol Biomarkers Prev; 2003 Jan; 12(1):34-41. PubMed ID: 12540501
[TBL] [Abstract][Full Text] [Related]
31. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial.
Thürlimann B; Hess D; Köberle D; Senn I; Ballabeni P; Pagani O; Perey L; Aebi S; Rochlitz C; Goldhirsch A
Breast Cancer Res Treat; 2004 Jun; 85(3):247-54. PubMed ID: 15111763
[TBL] [Abstract][Full Text] [Related]
32. Breast cancer prevention in community clinics: will low-income Latina patients participate in clinical trials?
Mandelblatt J; Kaufman E; Sheppard VB; Pomeroy J; Kavanaugh J; Canar J; Pallandre L; Cullen J; Huerta E
Prev Med; 2005 Jun; 40(6):611-8. PubMed ID: 15850856
[TBL] [Abstract][Full Text] [Related]
33. The impact of genetic counselling on risk perception and mental health in women with a family history of breast cancer.
Watson M; Lloyd S; Davidson J; Meyer L; Eeles R; Ebbs S; Murday V
Br J Cancer; 1999 Feb; 79(5-6):868-74. PubMed ID: 10070883
[TBL] [Abstract][Full Text] [Related]
34. "I'm going to die of something anyway": women's perceptions of tamoxifen for breast cancer risk reduction.
Paterniti DA; Melnikow J; Nuovo J; Henderson S; DeGregorio M; Kuppermann M; Nease R
Ethn Dis; 2005; 15(3):365-72. PubMed ID: 16108294
[TBL] [Abstract][Full Text] [Related]
35. The BCPT symptom scales: a measure of physical symptoms for women diagnosed with or at risk for breast cancer.
Stanton AL; Bernaards CA; Ganz PA
J Natl Cancer Inst; 2005 Mar; 97(6):448-56. PubMed ID: 15770009
[TBL] [Abstract][Full Text] [Related]
36. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
Goss PE
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
[TBL] [Abstract][Full Text] [Related]
37. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
38. Chemoprevention of breast cancer.
Dalton RR; Kallab AM
South Med J; 2001 Jan; 94(1):7-15. PubMed ID: 11213947
[TBL] [Abstract][Full Text] [Related]
39. Aromatase inhibitors for the treatment and prevention of breast cancer.
Kalidas M; Brown P
Clin Breast Cancer; 2005 Apr; 6(1):27-37. PubMed ID: 15899070
[TBL] [Abstract][Full Text] [Related]
40. [Interview with Prof. Dr. Wolfgang Eiermann. Which women need a medicamentous breast cancer prophylaxis?].
Eiermann W
MMW Fortschr Med; 2003 Dec; 145(50):8. PubMed ID: 14963963
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
